# A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors

> **NCT06772415** · PHASE1 · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 163 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** GenSci122 tablet 50mg
- **DRUG:** GenSci122 tablet 250mg

## Key facts

- **NCT ID:** NCT06772415
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2028-12
- **Final completion:** 2031-03
- **Target enrollment:** 163 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772415, "A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06772415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*